均衡法:干预后双重抗血小板治疗的理性方法
1Associate Director, Structural Heart Department, Jaslok Hospital & Research Centre, Mumbai, Maharashtra, India, Corresponding Author.
The Journal of the Association of Physicians of India
|November 20, 2024
概括
在药物释放支架放置后平衡出血和缺血风险至关重要. 双重抗血小板治疗 (DAPT) 是防止支架血栓形成和皮肤穿刺冠状动脉干预 (PCI) 后缺血事件的关键.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 用药物排泄支架 (DES) 进行冠状动脉血管塑造的患者面临缺血和出血事件的风险.
- 复发性缺血事件是心肌梗塞后患者的担忧,需要进行二次预防.
- 双抗血小板治疗 (DAPT) 是皮肤冠状动脉干预 (PCI) 后的标准护理,以预防支架血栓形成.
研究的目的:
- 探索在接受DES治疗的患者中缺血和出血风险之间的平衡.
- 审查目前关于PCI后DAPT持续时间的建议.
- 强调心肌梗塞幸存者的二次预防的重要性.
主要方法:
- 审查目前关于DAPT持续时间的医疗指南.
- 在PCI后的患者中分析与DAPT相关的风险.
- 讨论二次预防的治疗策略.
主要成果:
- 目前的指导方针建议在稳定的冠状动脉疾病中使用6个月的DAPT,在急性冠状动脉综合征 (ACS) 中使用12个月.
- DAPT的最佳持续时间包括平衡预防支架血栓塞与出血风险的平衡.
- 个体化的患者因素可能会影响DAPT持续时间的决定.
结论:
- 在DES植入后优化DAPT持续时间对于患者的治疗结果至关重要.
- 进一步的研究可能会根据患者特定的风险概况,完善对DAPT持续时间的建议.
- 有效的二次预防策略对于治疗冠状动脉疾病患者至关重要.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
469
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
469
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:26Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
01:22Formation of the Platelet Plug
4.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.5K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
141
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
141
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
3.9K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
3.9K